Gabapentin use and a claim for memory loss in Connecticut

Connecticut's dense population, high healthcare utilization rates, and proximity to New York City's pharmaceutical litigation infrastructure make it a significant jurisdiction for gabapentin cognitive decline claims. The state has among the highest rates of insured residents in the nation, meaning gabapentin access is broadly available and prescribing volumes are substantial relative to its 3.6 million population. Connecticut's opioid crisis — particularly severe in cities like New Haven, Hartford, and Bridgeport — drove increased gabapentin prescribing as physicians sought alternatives. The state's product liability statute provides strong plaintiff protections, and Connecticut courts have experience with complex pharmaceutical litigation.

For the overall process and updates, read the Gabapentin use and a claim for memory loss overview. This page covers the local information available for Connecticut.